267 related articles for article (PubMed ID: 32324888)
21. Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children.
Kurtzberg J; Prockop S; Chaudhury S; Horn B; Nemecek E; Prasad V; Satwani P; Teira P; Hayes J; Burke E;
Biol Blood Marrow Transplant; 2020 May; 26(5):855-864. PubMed ID: 32044400
[TBL] [Abstract][Full Text] [Related]
22. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.
Bay JO; Dhédin N; Goerner M; Vannier JP; Marie-Cardine A; Stamatoullas A; Jouet JP; Yakoub-Agha I; Tabrizi R; Faucher C; Diez-Martin JL; Nunez G; Parody R; Milpied N; Espérou H; Garban F; Galambrun C; Kwiatkovski F; Darlavoix I; Zinaï A; Fischer A; Michallet M; Vernant JP
Transplantation; 2005 Sep; 80(6):782-8. PubMed ID: 16210965
[TBL] [Abstract][Full Text] [Related]
23. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
[TBL] [Abstract][Full Text] [Related]
24. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
[No Abstract] [Full Text] [Related]
25. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
[TBL] [Abstract][Full Text] [Related]
26. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Munster P; Iannotti N; Cho DC; Kirkwood JM; Villaruz LC; Gibney GT; Hodi FS; Mettu NB; Jones M; Bowman J; Smith M; Lakshminarayanan M; O'Day S
Cancer Res Commun; 2023 Dec; 3(12):2572-2584. PubMed ID: 38115208
[TBL] [Abstract][Full Text] [Related]
27. Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials.
Luo C; Huang X; Wei L; Wu G; Huang Y; Ding Y; Huang Z; Chen J; Li X; Zou Y; Xu S
Front Immunol; 2023; 14():1211171. PubMed ID: 37409129
[TBL] [Abstract][Full Text] [Related]
28. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.
Kebriaei P; Hayes J; Daly A; Uberti J; Marks DI; Soiffer R; Waller EK; Burke E; Skerrett D; Shpall E; Martin PJ
Biol Blood Marrow Transplant; 2020 May; 26(5):835-844. PubMed ID: 31505228
[TBL] [Abstract][Full Text] [Related]
29. A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease.
Fløisand Y; Schroeder MA; Chevallier P; Selleslag D; Devine S; Renteria AS; Mohty M; Yakoub-Agha I; Chen C; Parfionovas A; Quadri S; Jansson J; Akbari M; Chen YB
Bone Marrow Transplant; 2021 Oct; 56(10):2477-2488. PubMed ID: 34108672
[TBL] [Abstract][Full Text] [Related]
30. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease.
Kurtzberg J; Abdel-Azim H; Carpenter P; Chaudhury S; Horn B; Mahadeo K; Nemecek E; Neudorf S; Prasad V; Prockop S; Quigg T; Satwani P; Cheng A; Burke E; Hayes J; Skerrett D;
Biol Blood Marrow Transplant; 2020 May; 26(5):845-854. PubMed ID: 32018062
[TBL] [Abstract][Full Text] [Related]
31. FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
Przepiorka D; Luo L; Subramaniam S; Qiu J; Gudi R; Cunningham LC; Nie L; Leong R; Ma L; Sheth C; Deisseroth A; Goldberg KB; Blumenthal GM; Pazdur R
Oncologist; 2020 Feb; 25(2):e328-e334. PubMed ID: 32043777
[TBL] [Abstract][Full Text] [Related]
32. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
Srinivas N; Barbour AM; Epstein N; Zhou G; Petusky S; Xun Z; Yuska B; Marbury T; Chen X; Yeleswaram S; Punwani N
J Clin Pharmacol; 2020 Aug; 60(8):1022-1029. PubMed ID: 32149388
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
[TBL] [Abstract][Full Text] [Related]
35. The utility of cognitive changes in identifying those with acute graft vs. host disease following allogeneic hematopoietic cell transplant.
Stratton J; Sylvia A; Hoodin F; Choi SW; Pawarode A; Giordani B; Votruba K
Clin Neuropsychol; 2020 Jul; 34(5):969-980. PubMed ID: 31619131
[No Abstract] [Full Text] [Related]
36. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
Naing A; Powderly JD; Nemunaitis JJ; Luke JJ; Mansfield AS; Messersmith WA; Sahebjam S; LoRusso PM; Garrido-Laguna I; Leopold L; Geschwindt R; Ding K; Smith M; Berlin JD
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288468
[TBL] [Abstract][Full Text] [Related]
37. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.
Mehta RS; Saliba RM; Jan A; Shigle TL; Wang E; Nieto Y; Ciurea SO; Oran B; Im J; Olson A; Marin D; Qazilbash M; Khouri I; Rondon G; Anderlini P; Rezvani K; Popat U; Kebriaei P; Shpall E; Champlin R; Alousi A
Transplant Cell Ther; 2021 Mar; 27(3):272.e1-272.e5. PubMed ID: 33781539
[TBL] [Abstract][Full Text] [Related]
38. α
Magenau JM; Goldstein SC; Peltier D; Soiffer RJ; Braun T; Pawarode A; Riwes MM; Kennel M; Antin JH; Cutler CS; Ho VT; Alyea EP; Parkin BL; Yanik GA; Choi SW; Lewis EC; Dinarello CA; Koreth J; Reddy P
Blood; 2018 Mar; 131(12):1372-1379. PubMed ID: 29437593
[TBL] [Abstract][Full Text] [Related]
39. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
40. Treatment and Nursing for Steroid-Refractory Acute Graft-Versus-Host Disease.
Cazeau N; Rodriguez SL
Clin J Oncol Nurs; 2023 Jul; 27(4):397-403. PubMed ID: 37677777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
